SEC Filing Summary: 180 Life Sciences Corp. (ATNF)
Business Context and Reporting Period
This Form 8-K, dated January 11, 2024, reports on a regulatory event concerning 180 Life Sciences Corp. (the "Company"). The filing addresses the Company's status regarding continued listing on the Nasdaq Capital Market following a notification of non-compliance with minimum stockholders' equity requirements.
Key Financial Metrics
The filing references the Company's financial position as of September 30, 2023, based on its Quarterly Report on Form 10-Q:
- Stockholders' Equity: Reported a deficit of ($149,327).
- Nasdaq Requirement: Minimum stockholders' equity of $2,500,000 required under Listing Rule 5550(b)(1).
- Compliance Status: The Company does not meet the minimum requirement nor the alternative continued listing standards.
The filing does not provide current revenue, profit, cash flow, or debt figures beyond the referenced equity deficit.
Material Changes and Regulatory Action
On November 15, 2023, Nasdaq notified the Company of its non-compliance. The Company submitted a plan to regain compliance by the January 2, 2024 deadline. On January 11, 2024, Nasdaq granted an extension to regain compliance.
- Extension Deadline: May 13, 2024.
- Goal: Complete transactions to increase stockholders' equity to more than $2.5 million.
- Evidence of Compliance: The Company must file a public report (e.g., Form 8-K) detailing the deficiency, the transaction enabling compliance, and an affirmative statement of compliance. Alternatively, it may submit a pro forma balance sheet no older than 60 days evidencing compliance.
Outlook, Risks, and Contingencies
Management is evaluating various courses of action to regain compliance but stated there can be no assurance that the contemplated transactions will be completed or will result in compliance within the granted period.
- Delisting Risk: If the Company fails to evidence compliance in its next periodic report (Quarter ended June 30, 2024), it may be subject to delisting.
- Appeal Process: In the event of a delisting determination, the Company may appeal to a Hearings Panel.
- Ongoing Monitoring: Nasdaq will continue to monitor ongoing compliance with the stockholders' equity requirement.
Key Facts for Investor Verification
- Verify the specific transactions planned to raise stockholders' equity above $2.5 million by May 13, 2024.
- Monitor the Company's next periodic report (Q2 2024) for evidence of regained compliance to avoid delisting.
- Review the Company's cash position and ability to fund operations while attempting to meet the equity requirement.
- Confirm whether the Company has elected Alternative 1 or Alternative 2 for evidencing compliance in future filings.